Alpha-1 antitrypsin deficiency: Whom to test, whom to treat?

Seminars in Respiratory and Critical Care Medicine

Volumn 31, Issue 3, 2010, Pages 343-347

  Sandhaus, Robert A ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

Alpha 1 antitrypsin deficiency; Augmentation therapy; Chronic obstructive pulmonary disease; Emphysema; Genetic testing

Indexed keywords

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; FORCED EXPIRATORY VOLUME; GENETIC PREDISPOSITION; LAW ENFORCEMENT; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW;

ALPHA 1-ANTITRYPSIN DEFICIENCY; DECISION MAKING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREJUDICE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 77953319553     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0030-1254074     Document Type: Review

References (26)

1. Silverman E K., Sandhaus R A. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009 360 2749-2757
2. Brantly M. Efficient and accurate approaches to the laboratory diagnosis of alpha1-antitrypsin deficiency: the promise of early diagnosis and intervention. Clin Chem 2006 52 2180-2181
3. de Serres F J., Blanco I, Fernández-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet 2003 64 382-397
4. Silverman E K., Miletich J P., Pierce J A. et al. Alpha-1-antitrypsin deficiency: high prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis 1989 140 961-966
5. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest 1986 89 370-373
6. Janoff A. Inhibition of human granulocyte elastase by serum alpha-1-antitrypsin. Am Rev Respir Dis 1972 105 121-122
7. Janoff A, Sandhaus R A., Hospelhorn V D., Rosenberg R. Digestion of lung proteins by human leukocyte granules in vitro. Proc Soc Exp Biol Med 1972 140 516-519
8. Janoff A. Elastases and emphysema: current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis 1985 132 417-433
9. Campos M A., Alazemi S, Zhang G, Wanner A, Sandhaus R A. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD 2009 6 31-40
10. Mayer A S., Stoller J K., Vedal S et al. Risk factors for symptom onset in PI Z alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2006 1 485-492
11. Fagerhol M K., Laurell C B. The Pi system-inherited variants of serum alpha 1-antitrypsin. Prog Med Genet 1970 7 96-111
12. Jeppsson J O., Laurell C B., Nosslin B, Cox D W. Catabolic rate of alpha1-antitrypsin of Pi types S, and MMalton and of asialylated M-protein in man. Clin Sci Mol Med 1978 55 103-107
13. Blundell G, Cole R B., Nevin N C., Bradley B. Letter: Alpha 1-antitrypsin null gene (pi-). Lancet 1974 2 404
14. Laurell C B., Eriksson S. The electrophoretic alpha-1-globulin pattern of serum in alpha-1 antitrypsin deficiency. Scand J Clin Lab Invest 1963 15 132-140
15. Sharp H L., Bridges R A., Krivit W, Freier E F. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med 1969 73 934-939
16. American Thoracic Society. Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1989 140 1494-1497
17. Fabbri L, Pauwels R A., Hurd S S., GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003. COPD 2004 1 105-141 discussion 103-104
18. Celli B R., MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004 23 932-946
19. American Thoracic Society European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003 168 818-900
20. Gadek J E., Klein H G., Holland P V., Crystal R G. Replacement therapy of alpha 1-antitrypsin deficiency: reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981 68 1158-1165
21. Wewers M D., Casolaro M A., Sellers S E. et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987 316 1055-1062
22. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998 158 49-59
23. Seersholm N, Wencker M, Banik N et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997 10 2260-2263
24. Chapman K R., Stockley R A., Dawkins C, Wilkes M M., Navickis R J. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009 6 177-184
25. Dirksen A, Piitulainen E, Parr D G. et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009 33 1345-1353
26. Shermock K M., Gildea T R., Singer M, Stoller J K. Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: a decision analysis. COPD 2005 2 411-418